{"disease":{"id":"staphylococcal-skin-infections","name":"staphylococcal skin infections"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT01419184","title":"Daptomycin Versus Vancomycin in Participants With Skin Infections Due to MRSA","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":250,"lead_sponsor_name":"Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","has_results":true},{"nct_id":"NCT02814916","title":"Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Children, Known or Suspected to be Caused by Susceptible Gram-positive Organisms, Including MRSA","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":199,"lead_sponsor_name":"AbbVie","has_results":true}],"total":2},"guidelines":[],"source":"Drug Landscape verified database"}